OrbiMed

OrbiMed Advisors LLC

[OrbiMed @OrbiMed]

Congratulations to @Crinetics on its agreement to be acquired by Vertex Pharmaceuticals for $10B!

OrbiMed has been proud to support Crinetics throughout its journey since 2018—from advancing a novel scientific platform to backing its IPO and beyond. This acquisition is a testament to the vision, dedication, and execution of the entire Crinetics team.

We look forward to seeing the continued impact these therapies for rare endocrine disorders and endocrine-related cancers will have on patients around the world.

https://t.co/NnM4mYzJT6

[OrbiMed @OrbiMed]

We're proud to partner with The Oncology Institute on its strategic refinancing, providing a new $75 million term loan that strengthens the company's balance sheet, extends debt maturities, and enhances financial flexibility. We appreciate the opportunity to support The Oncology Institute's mission and look forward to what's ahead.
https://t.co/k7P7xBaH9G

[OrbiMed @OrbiMed]

Congratulations to our portfolio company RayThera on its agreement to be acquired by Biogen for up to $1B!

RayThera is a small molecule drug discovery company focused on building an immunology pipeline for high unmet need indications.

Founded by Qing Dong and Gene Hung, OrbiMed helped launch the company as part of a $110M Series A in April 2025. Previously, OrbiMed had worked with Qing and Gene with their prior venture XinThera (acquired by Gilead).

https://t.co/BALIih6JDd

[OrbiMed @OrbiMed]

Congratulations to our portfolio company @STAR_Biotech on the sale of its wholly owned subsidiary, Vega Therapeutics, to Incyte for up to $2B.

Vega Therapeutics’ lead candidate, VGA039, modulates Protein S to improve hemostasis, potentially improving the body’s ability to control bleeding in numerous bleeding disorders. The transaction reflects Star Therapeutics' commitment to innovation to develop first-in-class and best-in-class therapies for serious conditions with high unmet need.

https://t.co/GQH2CeQn9g

[OrbiMed @OrbiMed]

Congratulations to our portfolio company @EdgewiseTx on the sale of sevasemten, in late-stage clinical trials for Becker and Duchenne muscular dystrophy, to Servier for up to $2.65B, including $1.55B upfront!

Edgewise leverages its deep expertise in muscle physiology to develop novel therapeutics and is led by OrbiMed Venture Partner Kevin Koch. This transaction sharpens the company's strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline.

https://t.co/iBOqqjZ9sS

[OrbiMed @OrbiMed]

Congratulations to our portfolio company, @CurevoVaccine, on its agreement to be acquired by Lilly for up to $1.5B!

OrbiMed first invested in Curevo as part of its 2025 Series B, based on the team’s differentiated approach to shingles vaccination. Curevo’s optimized version of a TLR4 agonist is well positioned to become a leading option for people seeking protection from shingles.

We were proud to support the company alongside OrbiMed Partner Tal Zaks, who served on the Board of Directors since 2025. Congratulations to the entire Curevo team on this important milestone.

https://t.co/q8oylCLeOA

[OrbiMed @OrbiMed]

Congratulations to our portfolio company Odyssey Therapeutics on its initial public offering!

OrbiMed first joined the Odyssey story in 2021, leading the company’s Series A financing to support its platform and pipeline focused on autoimmune and inflammatory diseases.

We are excited to see Odyssey reach this important milestone and looking forward to its continued progress as a public company.

https://t.co/tQ1ck6AmiP

[OrbiMed @OrbiMed]

Congratulations to @Path_AI on its agreement to be acquired by Roche in a transaction valued at up to $1.05B, including $750M upfront and up to $300M in additional milestone payments!

The deal builds on a partnership that began in 2021 to include the development of AI-enabled companion diagnostic algorithms. PathAI's AISight Image Management System is helping transform pathology into AI-driven workflows, accelerating diagnosis, supporting biomarker discovery, and advancing the shift toward personalised healthcare.

We are proud to have supported the company on this journey and congratulate the Path AI team on reaching this exciting milestone.

https://t.co/pckr1hNxKp

[OrbiMed @OrbiMed]

Congratulations to our portfolio company Perfuse Therapeutics on its agreement to be acquired by Bayer for up to $2.45B!

Perfuse was internally incubated at OrbiMed by Venture Partner Sevgi Gurkan, with the mission of improving retinal blood flow and addressing the underlying ischemic pathology driving diseases such as glaucoma and diabetic retinopathy. Beyond slowing the progression of vision loss, the approach has the potential to restore function in retinal cells compromised by poor perfusion.

Thanks to Peter Thompson, Bob Smith, and the many colleagues across the firm who worked alongside Sevgi to build the company from inception.

https://t.co/GORI5wIfX4

[OrbiMed @OrbiMed]

We’re pleased to share that our portfolio company Candid Therapeutics has entered into a definitive agreement to be acquired by UCB for up to $2.2B.

Candid, led by Ken Song, was built on a thesis of leveraging validated biology to develop differentiated, more convenient therapies for autoimmune disease. The team moved quickly to advance programs and generate encouraging clinical data across multiple indications.

We were excited to partner with Ken again in 2024, building on a prior successful collaboration. Congratulations to Ken and the Candid team on this outcome.

https://t.co/cCbKZ4IuvZ

[OrbiMed @OrbiMed]

We’re pleased to share that our portfolio company Noctrix has entered into an agreement to be acquired by ResMed for approximately $340M in cash.

Noctrix is pioneering wearable, prescription-grade therapeutics, with its lead product Nidra offering a first-in-class, non-invasive treatment for Restless Leg Syndrome (RLS).

OrbiMed first invested in 2021 at the proof-of-concept stage and supported the company through pivotal development, regulatory approval, reimbursement, and commercialization. We’re proud to have partnered closely with the team on this trajectory.

Congratulations to the Noctrix team. We look forward to seeing Nidra reach more patients through ResMed’s platform.

https://t.co/rJjRUPcGnl

[OrbiMed @OrbiMed]

Excited to partner with @EmergentCDMO on refinancing their term loan and amending their asset-backed loan facility.
https://t.co/RnTgD9NtKh

[OrbiMed @OrbiMed]

Congratulations to our portfolio company Sidewinder Therapeutics on their $137M Series B to advance precision bispecific ADCs into the clinic!
https://t.co/fA4lq33IMn

[OrbiMed @OrbiMed]

Congratulations to our portfolio company @InSilicoMeds on this exciting collaboration!

[Insilico Medicine @InSilicoMeds]

Big Pharma Doubles Down on AI—Insilico Medicine Is Redefining Drug Discovery, Securing $2.75B Collaboration with Eli Lilly and Company.

Read the latest release 👇https://t.co/7fKjUG9SUm
#AI #Biotech #Pharma #DrugDiscovery #Transformation #NextGenMedicine

[OrbiMed @OrbiMed]

Congratulations to our portfolio company @TernsPharma! Today, Merck announced it has entered into an agreement to acquire Terns Pharmaceuticals for approximately $6.7Bn in cash.

Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer. The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China to advance its growing pipeline of drugs that are optimized against clinically-validated targets.

https://t.co/wHJtJT0n4r

[OrbiMed @OrbiMed]

Congratulations to @myriadgenetics for receiving FDA approval of their MyChoice CDx Test as the companion diagnostic for Zejula for patients with ovarian cancer.

[Myriad Genetics @myriadgenetics]

Today we announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the Companion Diagnostic (CDx) for Zejula® (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer.

👉Read more: https://t.co/hTxkkVFuTK

[OrbiMed @OrbiMed]

We are excited to continue to partner with our portfolio company @CongruenceTx as they advance their portfolio of small molecule correctors into the clinic.
https://t.co/qVJGnpVa8r